Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ION269 in Adults With Down Syndrome (Hero Study)
NCT06673069Phase 1Terminated
- Sponsor
- Ionis Pharmaceuticals
- Start
- Dec 2024
- Primary completion
- Dec 2025
- Modality
- Modified DNA Oligonucleotides, Single-strand DNA, Antisense Oligonucleotides (ASOs)
- Countries
- 2
01
Overview
Phase 1, open-label trial of ION269 in Down syndrome and Alzheimer's disease (AD) (3 cohorts), sponsored by Ionis Pharmaceuticals. Primary endpoints: Number of Participants With Treatment-Emergent Adverse Events and Serious Adverse Events at 40 weeks, Number of Participants With Change from Baseline in Laboratory Assessments at 40 weeks and 6 more. Started Dec 2024; status: terminated.
02
Drugs
ION269
03
Conditions
Down syndromeAlzheimer's disease (AD)
Beyond the preview
Go deeper on NCT06673069.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06673069.